Skip to main content

The first and only FDA-approved treatment for EoE patients as young as 1 year weighing ≥15 kg

Are your EoE patients struggling but saying they're fine?

We Can Do More Than Fine.

DISCOVER THE PATIENTS

EoE, eosinophilic esophagitis. Not an actual patient.

Over 76,000 EoE patients treated since INITIAL approval in 20221,a

Discover long-term results across the three key pillars of EoE management in patients as young as 1 year2-4,b:

bData up to 52 weeks.

HISTOLOGY

SYMPTOMS

ENDOSCOPIC FEATURES

Adults/Adolescents
(12+ years)

Efficacy Results Safety Data

Not actual patients.

Children
(1-11 years)

Efficacy Results Safety Data

Not an actual patient.

aIQVIA National Source of Business (NSOB) data as of March 2026.

See The ACG Guideline Recommendations
DUPIXENT MyWay® Logo

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.

ACG, American College of Gastroenterology.

Discover DUPIXENT MyWay Program benefits

DUPIXENT MyWay ENROLLMENT FORMS
English Enrollment Form
Spanish Enrollment Form

Contact a Field
Representative

Connect with a DUPIXENT Field Representative to get answers to your
product-related questions.

CONTACT A REP